Brickell Biotech, Inc. (BBI)

0.2493 +0.1328 (+113.99%) As of 11:58AM EDT. Market open.

Brickell Biotech, Inc.

5777 Central Avenue
Suite 102
Boulder, CO 80301
United States
720 505 4755
https://www.brickellbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 16

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Reginald L. Hardy M.B.A., R.Ph.	Co-Founder & Chairman	76.83k	N/A	1958
Attorney Robert Busard Brown	CEO & Director	816.73k	N/A	1962
Mr. Andrew D. Sklawer	Co-Founder, Pres, COO & Sec.	559.58k	N/A	1984
Mr. Deepak Chadha	Chief R&D Officer	543.59k	N/A	1970
Mr. Albert Nicholas Marchio II	CFO and Principal Accounting & Financial Officer	N/A	N/A	1952
Mr. David R. Mcavoy J.D.	Gen. Counsel & Chief Compliance Officer	N/A	N/A	1963
Mr. Gary S. Walker	Chief Marketing Officer	N/A	N/A	1960
Aron Aizenstat M.B.A., P.M.P.	VP of Corp. Devel. & Operations	N/A	N/A	N/A
Ms. Sue Fattor	Head of Human Resource	N/A	N/A	N/A
Ms. Nancy Seretta	VP & Head of Clinical Operations	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Corporate Governance

Brickell Biotech, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.